Long‐term viral suppression and immune recovery during first‐line antiretroviral therapy: a study of an HIV‐infected adult cohort in Hanoi, Vietnam by Tanuma, Junko et al.
Long#term viral suppression and
immune recovery during first#line
antiretroviral therapy: a study of an HIV#
infected adult cohort in Hanoi, Vietnam
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Tanuma, J., S. Matsumoto, S. Haneuse, D. D. Cuong, T. V. Vu, P. T.
T. Thuy, N. T. Dung, et al. 2017. “Long#term viral suppression and
immune recovery during first#line antiretroviral therapy: a study
of an HIV#infected adult cohort in Hanoi, Vietnam.” Journal of the
International AIDS Society 20 (4): e25030. doi:10.1002/jia2.25030.
http://dx.doi.org/10.1002/jia2.25030.
Published Version doi:10.1002/jia2.25030
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014996
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
RESEARCH ARTICLE
Long-term viral suppression and immune recovery during first-line
antiretroviral therapy: a study of an HIV-infected adult cohort in
Hanoi, Vietnam
Junko Tanuma1,2 , Shoko Matsumoto1, Sebastien Haneuse3, Do Duy Cuong4, Tuong Van Vu4, Pham Thi Thanh
Thuy4, Nguyen Thi Dung5, Nguyen Thi Hoai Dung5, Nguyen Vu Trung5, Nguyen Van Kinh5 and Shinichi Oka1
Corresponding author: Junko Tanuma, AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku, Tokyo 162-8655, Japan.
Tel: +81-3-3202-7181 5642 (jtanuma@acc.ncgm.go.jp)
Abstract
Introduction: Achieving viral suppression is key in the global strategy to end the HIV epidemic. However, the levels of viral
suppression have yet to be described in many resource-limited settings.
Methods: We investigated the time to virologic failure (VF; defined as a viral load of ≥1000 copies/ml) and changes in CD4
counts since starting antiretroviral therapy (ART) in a cohort of HIV-infected adults in Hanoi, Vietnam. Factors related to the
time to VF and impaired early immune recovery (defined as not attaining an increase in 100 cells/mm3 in CD4 counts at
24 months) were further analysed.
Results: From 1806 participants, 225 were identified as having VF at a median of 50 months of first-line ART. The viral sup-
pression rate at 12 months was 95.5% and survival without VF was maintained above 90% until 42 months. An increase in
CD4 counts from the baseline was greater in groups with lower baseline CD4 counts. A younger age (multivariate hazard ratio
(HR) 0.75, vs. <30), hepatitis C (HCV)-antibody positivity (HR 1.43), and stavudine (d4T)-containing regimens (HR 1.4, vs. zido-
vudine (AZT)) were associated with earlier VF. Factors associated with impaired early immune recovery included the male sex
(odds ratio (OR) 1.78), HCV-antibody positivity (OR 1.72), d4T-based regimens (OR 0.51, vs. AZT), and nevirapine-based regi-
mens (OR 0.53, vs. efavirenz) after controlling for baseline CD4 counts.
Conclusion: Durable high-rate viral suppression was observed in the cohort of patients on first-line ART in Vietnam. Our
results highlight the need to increase adherence support among injection drug users and HCV co-infected patients.
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1 | INTRODUCTION
The increased accessibility to antiretroviral therapy (ART) has
dramatically reduced the mortality and morbidity of HIV-
infected individuals globally. Recent studies have also demon-
strated the significant benefits of early ART initiation and pre-
ventive ART use [1,2], which had accelerated ART promotion.
In 2014, the Joint United Nations Programme on HIV/AIDS
(UNAIDS) set the “90-90-90” goal, which aims to diagnose
90% of all HIV-infected individuals, provide ART to 90% of
diagnosed individuals, and achieve undetectable HIV RNA
levels in 90% of individuals receiving ART by 2020 [3].
According to the 90-90-90 strategy, the plasma HIV viral load
(VL) test is considered an essential tool to evaluate the pro-
gress of the third goal. Routine VL monitoring has been the
gold standard to detect treatment failure since the mid-1990s
in resource-rich countries, and the World Health Organization
(WHO) recommends VL monitoring after six months of ART
and then every 12 months whenever possible [2,4,5]. How-
ever, VL monitoring is still unavailable for many ART pro-
grammes in resource-limited countries, given the procedure’s
cost and complexity, which has limited information regarding
viral suppression rates in these regions.
VL monitoring identifies individuals who need additional
support to adhere to their ART regimen or when to switch
from the current regimen to salvage ART, which can facilitate
effective resource allocation and investment. Vietnam has
recently expanded ART programme with a coverage rate of
68% by the end of 2013 [6], although most patient groups
have not experienced the benefits of VL monitoring. The HIV
epidemic in Vietnam is strongly associated with injection drug
use (IDU; 45%) and transmission to their sexual partners [6],
and the overall virologic outcome of ART may be influenced
by the social and epidemiological characteristics of these high-
risk groups. Several previous studies, including three Viet-
namese studies, have revealed suboptimal adherence to ART
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among drug users [7–11], although those studies only exam-
ined small target populations during short study periods [11–
16]. As ART requires lifelong optimal adherence to experience
its full benefits, it would be preferable to examine long-term
virologic outcomes that are related to treatment failure, such
as death and loss to follow-up. Therefore, we aimed to deter-
mine the time to virologic failure (VF), which was defined as
having an HIV VL of ≥1000 copies/ml during first-line ART
[4], as well as longitudinal immune recovery, and their related
risk.
2 | METHODS
2.1 | Study setting and population
Analyses were conducted with a longitudinal dataset from the
Hanoi HIV Cohort Study [17], which was established in Octo-
ber 2007 in two large hospitals in urban Hanoi, Vietnam,
namely National Hospital of Tropical Diseases (NHTD) and
Bach Mai Hospital (BMH); both of these hospitals are teach-
ing and referral hospitals and provide free ART programmes.
HIV-infected individuals aged 18 years or above were consec-
utively enrolled from October 2007 to April 2013 and fol-
lowed up until April 2015.
For this study, we enrolled patients who were on ART
since October 2007 to March 2012 and extended the eligi-
bility to untreated patients in April 2012. Retrospective and
prospective data were obtained at the time of enrolment
and every six months during ART and included all ART his-
tories and reasons for ART change. Free VL testing had
been provided as part of the programme, using the
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test system
(Roche Diagnostics Ltd., Rotkruez, Switzerland). The VL test-
ing was performed every six months until an undetectable
VL was observed, and was subsequently performed at least
annually thereafter. Genotypic drug resistance testing was
performed for participants with a VL of >1000 copies/ml.
The test results were returned to the treating physicians,
and the ART was switched to a salvage regimen for partici-
pants with a VL of >1000 copies/ml with any drug resis-
tance mutation or two consecutive VLs of >1000 copies/ml.
Patients who had no VL test results during first-line ART,
were on ART for less than 7 days, or had started with
mono/dual therapy or regimens that contained protease inhi-
bitor or nucleos(t)ide reverse transcriptase inhibitor (NRTI)
combinations other than zidovudine (AZT), stavudine (d4T),
or tenofovir (TDF) plus lamivudine (3TC) or emtricitabine
(FTC), were excluded from the analyses. Diagnosis, prophy-
laxis, and treatment of opportunistic infections and indication
and selection of antiretroviral drugs were decided based on
the Vietnamese national guidelines [18–20], which were
updated twice during the study period according to changes
in the WHO guidelines [4,21,22]. The CD4 count for ART
indication was increased from 200 to 250 cells/mm3 in
2009 [19] and to 350 cells/mm3 in 2011 [20]. AZT and
d4T were replaced with TDF as the preferred first-line drug
in 2011 [20].
The study protocol was approved by the ethics committee
in the Vietnamese Ministry of Health (No: 1666/QD-BYT) and
the institutional ethical review boards in BMH, NHTD, and
the National Center for Global Health and Medicine in Tokyo,
Japan (NCGM-G-001074-01). All study participants provided
written informed consent before study enrolment.
2.2 | Statistical analysis
The time from ART initiation to treatment failure was anal-
ysed based on VF or a combined clinical endpoint, which was
defined as the first episode of death, or change in ART drug
due to lack of efficacy or VF after ≥6 months of first-line ART.
First-line ART was defined as the ART prescribed for the first
time in the patient’s life and was considered to be continued
until the last clinic visit or a change in ART due to lack of effi-
cacy. Loss to follow-up was defined as cases of patients whose
data for 12 months before the last day of data collection in
the database were not found, and the date of the last clinic
visit was used as the date of loss to follow-up. For both end-
points, the patients were censored at the end of the observa-
tion period or when they were transferred to another clinic.
In addition, patients were censored in the VF analysis in cases
of death, loss to follow-up, or change in the ART. The baseline
CD4 cell count at ART initiation was defined as the closest
CD4 measurement prior to and within three months of ART
initiation. The mean CD4 count and mean CD4 count change
trajectories were estimated using linear regression with the
outcome as a function of time (in years). For the latter, to
ensure flexibility in the estimated shape of the trajectories, we
used a natural cubic spline with three knots at six months,
three years, and six years [23,24].
We analysed the risk factors for early VF using the Cox
proportional hazards model, and a logistic regression model
was used to analyse the risk factors for failed early immune
recovery, which was defined as not achieving an increase in
CD4 counts of 100 cells/mm3 at 24 months. Both analyses
included the following covariates: age at ART initiation, sex at
birth, AIDS history before ART, baseline CD4 count, previous
IDU, a positive hepatitis B virus surface antigen (HBs antigen)
result, a positive anti-hepatitis C virus antibody (HCV-anti-
body) result, and antiretroviral categories of NRTIs (AZT, d4T,
or TDF) and non-nucleoside reverse-transcriptase inhibitors
(nevirapine (NVP) or efavirenz (EFV)). Variables that were sig-
nificant for the univariate analysis (p < 0.10) were chosen for
the multivariate analysis and considered statistically significant
at p < 0.05 in the final model. The chi-square test was used to
evaluate the association between IDU history and HCV-anti-
body positivity. All statistical analyses were performed using
STATA software (version 12; StataCorp LP, College Station,
TX, USA) and R Statistical Software (version 3.2.0; Foundation
for Statistical Computing, Vienna, Austria) [23].
3 | RESULTS
3.1 | Baseline characteristics
Between October 2007 and May 2013, 2156 HIV-infected
individuals were enrolled in the Hanoi HIV Cohort Study. This
study excluded 350 patients, including 185 patients who
never underwent ART, 48 patients who underwent ART for
less than six months, 96 patients whose initial ART did not
match the study criteria, 15 patients without VL results during
their first-line ART, five patients whose ART start date was
unknown, and one patient who was ≤18 years old at the start
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of ART. The remaining 1806 patients provided 7752 person-
years of follow-up and were assigned to the survival analysis
with virologic outcome categories. Data of 1441 patients with
available baseline CD4 counts were used for CD4 count and
CD4 count change trajectories, and 1013 of the 1441
patients who had CD4 results at 24 months were assigned to
the immune recovery analysis category. The characteristics of
study participants are summarized in Table 1. Overall, 64% of
the participants were men and the median age was 31 years
(range, 18–75). Thirty-two percent declared previous IDU, and
45% had HCV co-infection, which strongly indicates exposure
to sharing multiple needles. The median baseline CD4 count
was greater after 2011, compared to before 2011, which was
related to the updated ART indication in the national guideli-
nes (before 2011 median 100 cells/mm3 (ranged 1–671) vs.
after 2,011,158 cells/mm3 (ranged 1–693)).
3.2 | Time to VF and combined clinical endpoints
In a median time of 50 months of first-line ART, 225 individu-
als (12.4%) experienced VF, which corresponded to an inci-
dence of 2.9/100 person-years. Among these 225 individuals,
47 individuals were identified as having a VL ≥1000 copies/ml
within 12 months and 18 individuals subsequently achieved
an undetectable VL. The combined clinical endpoint was
detected for 311 individuals, which corresponded to an inci-
dence of 4.0 cases/100 person-years. These cases included
225 cases of VF, 36 deaths, and 50 cases of loss to follow-up.
By dividing the group that received a VL test by the group
with VLs below each threshold, we observed that the propor-
tion of viral suppression at 12 months was calculated to be
95.5% (1329/1391) for a threshold of 1000, 92.9% (1292/
1391) for a threshold of 200, and 80% (1112/1391) for a
threshold of 1000. Figure 1 illustrates the survival curves with
neither VF nor the combined clinical failure. The probability of
survival without VF was maintained above 90% until
42 months of first-line ART, with probabilities of 86% at five
years and 78% at ten years. The probability of survival with-
out the combined clinical endpoint was 80% at five years and
70% at ten years.
In the univariate analyses, earlier VF was associated with
IDU, HCV-antibody positivity, and d4T use were associated
with an earlier VF. However, protective effects were observed
for age ≥30 years, HBs antigen positivity, a baseline CD4
count of ≥200 cells/mm3, and an EFV-based regimen showed
significant protective effects (Table 2). Of these factors, we
found HCV-antibody positivity was strongly associated with
IDU history (p < 0.001) with 83% concordance, which may
have affected the result of the multivariate analysis when both
factors were integrated into the same multivariate model. As
individuals with IDU may have been reluctant to disclose their
IDU, we considered the presence of antibodies to HCV a bet-
ter indicator of sharing needs, compared to a self-reported
history of IDU. Thus, we developed two multivariate models,
with one that included all significant factors in the univariate
model (Model 1-1) and another that included all significant
factors except IDU (Model 1-2). Model 1-1 revealed a signifi-
cant result for age of >30 years, while Model 1-2 also
revealed a significant result for antibodies to HCV.
In the univariate analyses, the combined clinical endpoint
was associated with the male sex, IDU, HCV-antibody
positivity, and d4T. However, protective effects were observed
for age of >30 years and a baseline CD4 count of ≥200 cells/
mm3. We also developed two multivariate models for the com-
bined clinical endpoint (Model 2-1 and Model 2-2) and both
models provided similar results, with shorter survival being
significantly predicted by antibodies to HCV and d4T use.
Table 1. Characteristics of study participants
Total
Immune
recovery study
Number of participants 1806 1013
Median age at starting ART 31 (18–75) 34 (18–75)
<30 years old 668 (37) 352 (35)
30 to 39 years old 845 (47) 495 (49)
≥40 years old 293 (16) 166 (16)
Male sex 1156 (64) 642 (63)
HIV risk factors (multiple
possible)
Sexual contact 1334 (74) 755 (75)
Injection drug use, n (%) 583 (32) 308 (30)
Other/unknown 126 (7) 74 (7.3)
HBs antigen
Positive 242 (14) 135 (14)
Negative 1507 (86) 863 (86)
Missing 57 15
Anti-HCV antibody
Positive 737 (45) 385 (42)
Negative 897 (55) 527 (58)
Missing 172 101
AIDS before ART 307 (17) 202 (20)
Median baseline CD4
count (/mm3)
101 (1 to 693) 81 (1 to 693)
<100 712 (39) 556 (55)
100 to 199 377 (21) 266 (26)
≥200 352 (19) 191 (19)
Missing 365 -
Median time on ART, months 50 (6–152) 53.5 (7–119)
Year of ART initiation
≤2008 514 (29) 203 (20)
2009 to 2010 518 (28) 384 (38)
≥2011 774 (43) 426 (42)
NRTI
AZT + 3TC or FTC 832 (46) 523 (52)
d4T + 3TC or FTC 608 (34) 349 (34)
TDF + 3TC or FTC 366 (20) 141 (14)
NNRTI
NVP 958 (53) 556 (55)
EFV 848 (47) 457 (45)
Data are reported as number (%) or median (range). ART, antiretrovi-
ral therapy; HBs antigen, hepatitis B surface antigen; HCV, hepatitis C
virus; NRTI, nucleos(t)ide reverse transcriptase inhibitors; AZT, zidovu-
dine; d4T, stavudine; TDF, tenofovir; 3TC, lamivudine; FTC, emtric-
itabine; NNRTI, non-nucleoside reverse-transcriptase inhibitors; NVP,
nevirapine; EFV, efavirenz.
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3.3 | Immune recovery during first-line ART
Figure 2 shows that the absolute CD4 counts in 1441
patients increased over time regardless of their baseline
CD4 count categories <100 cells/mm3, 100 to 199 cells/
mm3, or ≥200 cells/mm3. Although 95% confidence intervals
are not shown in Figure 2, the three baseline category-speci-
fic intervals crossed at approximately 6.5 years. The mean
change in CD4 count was 155 cells/mm3 in the first year
and 255 cells/mm3 at 24 months (Figure 2b) with 167 of
1013 (16.5%) individuals failing to achieve early immune
recovery.
In the univariate model, impaired early immune recovery
was associated with the male sex, IDU, and HCV-antibody
positivity. Protective effects were observed for d4T and EFV
(Table 3) other than baseline CD4 categories. Given the
strong association between HCV-antibody positivity and IDU
mentioned above, we also developed models for impaired
early immune recovery that did and did not incorporate IDU
history (Model 3-1 and Model 3-2). Both models provided
similar results compared to the univariate models, although
IDU was a significant factor in Model 3-1.
4 | DISCUSSION
This study is the first to address the long-term virologic effi-
cacy of first-line ART in Vietnam, and to explore factors that
were related to VF and early immune recovery. The results
revealed high-level durable viral suppression and favourable
CD4+ recovery. A younger age and HCV co-infection were
associated with early VF and immune recovery at 24 months
was more likely to be impaired among men and individuals
with HCV co-infection. The currently recommended EFV-con-
taining regimen was associated with a lower VF rate and
higher early immune recovery rate, compared to the NVP-con-
taining regimen, and d4T was associated with a higher VF rate
than AZT.
The viral suppression rate at 12 months in this study
(95.5%) was comparable to that of a previous study (93.5%)
[15] and was higher than that of previous small studies in
Vietnam (70% to 78%) [12–16]. Furthermore, the 80% sup-
pression at 12 months based on a threshold VL of 50 copies/
ml was comparable to that observed in resource-rich coun-
tries [25]. Consistently favourable outcomes were even
observed for the combined clinical endpoint, which accounted
for death/loss to follow-up and eliminated bias caused by early
censoring of these outcomes [25]. Similarly, our previous stud-
ies that revealed a high retention rate in care and low mortal-
ity in this cohort [17,26]. The excellent virologic outcome in
our study strongly supports the achievability of Vietnam’s goal
to end AIDS by 2030 [6] in addition to the UNAIDS 90-90-90
goal [3].
We found that VF was associated with age of <30 years
and antibodies to HCV, although self-reported IDU was not
significantly associated with VF. Given the legal consequences
of IDU in Vietnam and the strong link between IDU and HCV
acquisition, it is highly probable that IDU was underreported
by the patients and should still be considered a risk for VF.
Previous studies have also reported that younger age and
IDU were associated with suboptimal adherence to ART
[15,26]. Our results indicated that these populations need
more support for ART adherence. In addition, we unexpect-
edly found that individuals with HBs antigen were less likely
to develop VF, which may be related to the management of
hepatitis in the national ART guidelines [19,20,28], which state
that cessation of an anti-HBV drug in an ART regimen may
have motivated physicians and patients not to miss a dose.
Furthermore, a lower baseline CD4 count (<200 cells/mm3)
was associated with a higher risk of VF in the univariate
model, which has also been observed in previous studies [15].
A lower baseline CD4 count might be the result of a combina-
tion of social and clinical factors. For example, a late diagnosis
of HIV, behaviour wherein individuals reduced likelihood of
seeking care, barriers to accessing healthcare, and lack of
appropriate knowledge among healthcare providers on when
to start ART are plausible risk factors for VF among those
with lower baseline CD4 counts. However, having AIDS prior
to ART was not associated with VF, although most AIDS
patients in this cohort had tuberculosis (TB) and the mortality
of HIV/TB co-infection was relatively low, compared to that in
other resource-limited countries [17]. Since TB treatment also
requires strict adherence, the additional involvement of a TB
specialist may increase the likelihood that the patient adheres
to the ART.
This study revealed that d4T use was associated with a
higher probability of VF than AZT, even though previous clini-
cal trials had revealed minimal difference in virologic efficacy
between d4T and AZT [29]. However, EFV use was associated
with a lower probability of VF compared to NVP in the uni-
variate model, which was further supported by data for both
in vitro potency [30] and from previous clinical trials [31–33].
Figure 1. Time to virologic failure (VF) or the combined clinical
endpoint during the first-line ART. The black line indicates the
probability of not achieving virologic endpoint and the red line indi-
cates the probability of not achieving the combined clinical end-
point. The virologic endpoint was defined as the first episode of
VF, (a viral load of ≥1000 copies/ml after starting ART. The com-
bined clinical endpoint was defined as the first episode of either
VF, death, loss to follow-up or switching to a salvage regimen.
ART, antiretroviral therapy.
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One possible reason for the inferiority of d4T in this study
might be suboptimal adherence, which could be caused by
side effects that are related to mitochondrial toxicity. Never-
theless, it is difficult to assess the actual effects of a single
antiretroviral agent on virologic outcome in real-world set-
tings. The Vietnamese national guideline previously recom-
mended d4T/3TC/NVP for first-line ART regimens [18],
although the recommendations were changed to AZT and
EFV in 2009 [19] and then the combination of TDF/EFV plus
3TC [20] in 2011. Moreover, d4T has been very rapidly
phased out of use since 2011 based on global concerns
regarding mitochondrial toxicity [22]. Thus, d4T was more fre-
quently used with NVP than EFV, while TDF, which has a high
genetic barrier [34], was exclusively used with EFV. Therefore,
although it is difficult to evaluate the efficacy of every specific
regimen, our data may suggest that the current recommenda-
tion of TDF/3TC or FTC/EFV is more beneficial than d4T- or
NVP-containing regimens.
We examined the longitudinal immune recovery that occurs
during first-line ART and explored factors related to early
immune recovery. A relatively large change in CD4 counts
was observed early during the ART, which agrees with the
findings of other studies [35,36]. However, the rate of
increase in CD4 counts was slightly faster in the groups with
lower baseline CD4 counts. Our analyses revealed that it took
approximately 6.5 years for the mean CD4 count trajectories
to become indistinguishable based on overlapping the 95%
confidence, which supports the recent global trend toward
early ART initiation [2,27].
We found that male sex, IDU, and HCV-antibody positivity
were related to impaired early immune recovery, which
agrees with the findings of previous studies [37,38]. In this
context, chronic immune activation by HCV co-infection may
lead to further immune dysfunction [38] and liver cirrhosis
may contribute to low leukocyte counts. This relationship is
particularly important in Vietnam, where HCV co-infection is
distinctly frequent among male HIV-infected individuals. In
addition, AZT use was linked to impaired early immune
recovery, while EFV use was associated with a more favour-
able early immune recovery. The mechanisms whereby AZT-
containing regimens cause impaired immune recovery remain
unclear, although the relationship is commonly accepted and
generally explained by AZT-related bone marrow suppres-
sion. Although the immune recovery in EFV-based regimens
h is generally considered similar to that in NVP-based regi-
mens [39,40], there remains controversy regarding which
drug provides the better CD4 response h. Nevertheless,
EFV is preferred for Vietnamese patients who are co-
infected with HCV than NVP based on concerns regarding
the hepatic toxicity of NVP [19,20,27], which may eventually
provide an immune recovery benefit among HCV co-infected
patients.
Figure 2. CD4 count trajectory during the first-line ART (a) The mean absolute CD4 counts during the first-line ART, (b) The mean CD4
count change from baseline during the first-line ART. ART, antiretroviral therapy.
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This study had limitations. First, there was a lack of infor-
mation about adherence to ART and other factors that could
affect it such as alcohol consumption and mental health status
[9]. Second, the baseline VL was not obtainable for all partici-
pants, and a high baseline VL is a known risk factor for VF.
Third, the baseline CD4+ count was also unavailable for 365
patients (20%), which may obscure the precise effect of the
baseline CD4+ count in our analyses. Fourth, the duration of
ART at cohort enrolment was diverse, especially when the
enrolment was started in 2007. Thus, the cohort may not
include patients who died shortly after starting ART before
2007 and the survival outcome could be overestimated.
Finally, both participating clinics were located in large urban
referral hospitals in Hanoi, and it remains unclear whether our
results are generalizable to other centres.
In conclusion, our study is the first study to describe the
long-term probability of viral suppression and immune recov-
ery during first-line ART in Vietnam. The viral suppression rate
was 95.5% at 12 months and the survival rate without VF
was maintained at 90% for 42 months. Younger age and
HCV-antibody positivity were associated with early VF, while
male sex, IDU, and HCV co-infection were associated with
impaired immune recovery at 24 months. EFV-containing regi-
mens provided\ better virologic outcomes and greater early
CD4 recovery, compared to d4T-containing regimens, which
had a higher rate of VF. Although we observed durable viral
suppression, our results suggest that increased support is
needed to help patients with IDU or HCV co-infection adhere
to their ART. Our findings also support the current global
trend toward wide-spread routine VL testing, which can facili-
tate more effective adherence support interventions.
AUTHORS ’ AFF I L IAT IONS
1AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo,
Japan; 2Takemi Program in International Health, Harvard T.H. Chan School of
Public Health, Boston, MA, USA; 3Department of Biostatistics, Harvard T.H.
Chan School of Public Health, Boston, MA, USA; 4Bach Mai Hospital, Hanoi,
Vietnam; 5National Hospital of Tropical Disease, Hanoi, Vietnam
COMPET ING INTERESTS
The authors have declared that no competing interests exist.
AUTHORS ’ CONTR IBUT IONS
Study concept and design: JT, SM, SH, KNV, SO; Collection and interpretation
of data: JT, SM, DNT, HDNT, CDD, VVT, TTP, TNV. Drafting the manuscript: JT,
SH; Statistical analysis: JT, SH; Obtained funding: SO.
ACKNOWLEDGEMENTS
We thank Ms. Nguyen Thi Yen, Ms. Nguyen Thi Tien, Ms. Nguyen Lan Phuong,
Ms. Le Thi Hoa, Mr. Pham Hong Hai, Dr. Nguyen Thi Ngoc Chi, and Dr. Dang
Thi Bich for collecting data. We also thank Ms. Kyoko Ishigaki, Ms. Keiko Saito
and Ms. Nguyen Thi Huyen for their assistance in performing the study.
Table 3. Risk factors for impaired early immune recovery after 24 months of the first-line ART
n = 1013 Univariate, OR (95% CI), p
Multivariate, OR (95% CI), p
Model 3-1 Model 3-2
Age at starting ART (years old)
<30 1.00 1.00 1.00
30 to 39 1.21 (0.83 to 1.76), 0.33 1.36 (0.90 to 2.06), 0.15 1.36 (0.90 to 2.06), 0.15
≥40 1.30 (0.79 to 2.13), 0.30 1.31 (0.74 to 2.31), 0.36 1.30 (0.73 to 2.28), 0.38
Gender male 1.50 (1.04 to 2.16), 0.03 1.78 (1.10 to 2.87), 0.017 1.86 (1.19 to 2.93), 0.007
Injection drug use 1.43 (1.00 to 2.02), 0.046 1.19 (0.69 to 2.06), 0.53
HBs antigen positive 0.66 (0.38 to 1.15), 0.14
Anti-HCV antibody positive 1.46 (1.03 to 2.07), 0.03 1.72 (1.01 to 2.91), 0.04 1.89 (1.22 to 2.92), 0.004
AIDS before ART 0.71 (0.46 to 1.12), 0.14
Baseline CD4 count (/mm3)
<100 1.00 1.00 1.00
100 to 199 2.95 (1.97 to 4.41), <0.001 2.95 (1.90 to 4.59), <0.001 2.95 (1.90 to 4.60), <0.001
≥200 3.53 (2.30 to 5.42), <0.001 3.49 (2.15 to 5.65), <0.001 3.48 (2.15 to 5.65), <0.001
NRTI
AZT + 3TC or FTC 1.00 1.00 1.00
d4T + 3TC or FTC 0.45 (0.29 to 0.67), <0.001 0.51 (0.32 to 0.82), 0.005 0.52 (0.33 to 0.83), 0.003
TDF + 3TC or FTC 0.86 (0.53 to 1.39), 0.53 1.30 (0.74 to 2.29), 0.36 1.30 (0.74 to 2.28), 0.37
Key drug
NVP 1.00 1.00 1.00
EFV 0.59 (0.42 to 0.84), 0.003 0.53 (0.28 to 0.70), <0.001 0.44 (0.28 to 0.70), <0.001
Impaired immune recovery was defined as failing to attain 100/ll increase in CD4 count in 24 months of the first-line ART. Factors provide
p > 0.1 in univariate model were included in the multivariate models. Factors with p-value less than 0.1 in the univariate model were included in
the multivariate models. Confidential intervals that do not overlap the null value of HR=1 are shown in bold. OR, odds ratio; CI, confidential inter-
val; ART, antiretroviral therapy; HBs antigen, hepatitis B surface antigen; HCV, hepatitis C virus; NRTI, nucleos(t)ide reverse transcriptase inhibi-
tors; AZT, zidovudine; d4T, stavudine; TDF, tenofovir; 3TC, lamivudine; FTC, emtricitabine; NNRTI, non-nucleoside reverse-transcriptase inhibitors;
NVP, nevirapine; EFV, efavirenz.
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